Search by Categories
- Insights
- Rare Disease
- Oncology
- Cell and Gene Therapy
- Medical Devices
- Consulting
- News & Analysis
-
Therapeutic Areas
Our expertise in the industry
Ipsen and Skyhawk Therapeutics Partnership; SynOx Therapeutics’ Phase III Trial; Roche’s Alecensa FDA Approval; AbbVie’s RINVOQ Phase III SELECT-GCA Trial; AskBio’s AB-1002 FDA Fast Track Designation
Ipsen Partners with Skyhawk Therapeutics for RNA-Focused Research in Rare Neurological Disorders Ipsen and Skyhawk Therapeutics have entered into an exclusive global partnership to explore and create new small molecules that can influence RNA for rare neurological conditions. Under this agreement, Ipsen has the option to obtain exclusive rights worldwide for developing promising candidates resulting from the collaboration. Once successful candidates are identified, Ipsen will oversee all subsequent activities. Skyhawk's innovative platform expedites the development of small molecules targeting RNA in various therapeutic domains, particularly focusing on rare neurological disorders.…
Empowering Change: REZDIFFRA’s Trailblazing Journey in NASH Treatment
Liver disease emerges as a burgeoning global health concern, presenting a myriad of formidable challenges. From viral hepatitis to alcoholic liver disease, nonalcoholic fatty liver disease (NAFLD), liver cirrhosis, and hepatocellular carcinoma (HCC), these conditions collectively afflict millions, exacting a toll of morbidity, mortality, and economic burden. Within this landscape, NAFLD/nonalcoholic steatohepatitis (NASH) recently renamed MASH (metabolic dysfunction-associated steatohepatitis) assumes prominence as a pivotal contributor. NAFLD, a comprehensive term encapsulating a spectrum of liver afflictions, encompasses everything from benign steatosis to progressive hepatocellular injury accompanied by fibrosis, cirrhosis, and, in…
Breakthroughs in Parkinson’s Management: Key Findings from Neuroderm’s ND0612 Studies
NeuroDerm's ND0612 introduces a pioneering approach to Parkinson's disease management with its self-administered continuous subcutaneous infusion of levodopa/carbidopa. Unlike traditional oral formulations, ND0612 bypasses the gastrointestinal tract, offering increased bioavailability and potentially more reliable relief from motor fluctuations By providing a continuous, adjustable dose of levodopa/carbidopa via subcutaneous infusion, ND0612 aims to extend the therapeutic window for Parkinson's patients. This innovative approach seeks to minimize motor fluctuations and optimize patients' "ON" time, thereby offering greater daily-life predictability and independence compared to conventional oral treatments Neuroderm made a significant impact at…